IMA 202

Drug Profile

IMA 202

Alternative Names: IMA202

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immatics US
  • Developer Immatics US; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 01 Mar 2018 Immatics US and M.D. Anderson Cancer Center plans a phase I trial for Hepatocellular-carcinoma (Second line therapy or greater) and Non-small-cell-lung-cancer (Second line therapy or greater, Recurrent, Late stage disease, Metastatic disease) in USA (NCT03441100), in March 2018
  • 23 Feb 2018 Phase-I/II clinical trials in Cancer in USA (Parenteral) (Immatics pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top